TY - JOUR
T1 - Differences in MDS-UPDRS Scores Based on Hoehn and Yahr Stage and Disease Duration
AU - Skorvanek, Matej
AU - Martinez-Martin, Pablo
AU - Kovacs, Norbert
AU - Rodriguez-Violante, Mayela
AU - Corvol, Jean Christophe
AU - Taba, Pille
AU - Seppi, Klaus
AU - Levin, Oleg
AU - Schrag, Anette
AU - Foltynie, Thomas
AU - Alvarez-Sanchez, Mario
AU - Arakaki, Tomoko
AU - Aschermann, Zsuzsanna
AU - Aviles-Olmos, Iciar
AU - Benchetrit, Eve
AU - Benoit, Charline
AU - Bergareche-Yarza, Alberto
AU - Cervantes-Arriaga, Amin
AU - Chade, Anabel
AU - Cormier, Florence
AU - Datieva, Veronika
AU - Gallagher, David A.
AU - Garretto, Nelida
AU - Gdovinova, Zuzana
AU - Gershanik, Oscar
AU - Grofik, Milan
AU - Han, Vladimir
AU - Huang, Jing
AU - Kadastik-Eerme, Liis
AU - Kurtis, Monica M.
AU - Mangone, Graziella
AU - Martinez-Castrillo, Juan Carlos
AU - Mendoza-Rodriguez, Amelia
AU - Minar, Michal
AU - Moore, Henry P.
AU - Muldmaa, Mari
AU - Mueller, Christoph
AU - Pinter, Bernadette
AU - Poewe, Werner
AU - Rallmann, Karin
AU - Reiter, Eva
AU - Rodriguez-Blazquez, Carmen
AU - Singer, Carlos
AU - Tilley, Barbara C.
AU - Valkovic, Peter
AU - Goetz, Christopher G.
AU - Stebbins, Glenn T.
N1 - Funding Information:
Ethical Compliance Statement: We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this work is consistent with those guidelines. Funding Sources and Conflict of Interest: The funding for research leading to this study was provided by the Slovak Research and Development Agency under contract no. APVV-14-0415 and by the Slovak Scientific Grant Agency under contract no. VEGA 1/0024/14; by the Movement Disorder Society, which received partial support from UCB Spain; from the program “Investissements d’Avenir” ANR-10-IAIHU-06; by Grant PUT1239 from the Estonian Research Council; by the Bolyai Scholarship of the Hungarian Academy of Sciences (OTKA PD103964) and the Hungarian Brain Research Program (Grant KTIA_13_NAP-A-II/10; government-based funds); by Parkinson’s UK (G-0508); and by the Austrian Science Fund (FWF Project: KLI82-B00). Christopher G. Goetz, Glenn T. Stebbins, Pablo Martinez-Martin, and Anette Schrag developed the MDS-UPDRS scale. Matej Skorvanek, Pablo Martinez-Martin, Norbert Kovacs, Pille Taba, and Oleg Levin served as principal investigators in the translation phase of the MDS-UPDRS in their respective languages. The authors report no sources of funding and no conflicts of interest relevant to this work. Financial disclosures for the past 12 months: M.S. received grants from the Slovak Research and Development Agency and the Slovak Scientific Grant Agency as well as speaker’s honoraria and compensation for consultations from AbbVie, Actavis, Egis, Krka, Lundbeck, Medtronic, TEVA, and UCB. J.C.C. received honoraria for participating to scientific advisory boards for BMS, Zambon, Pfizer, and AbbVie; a research grant from Ipsen; travel grants from AbbVie and Zambon; and owns stock in B&A Therapeutics. M.R.V. has received honoraria from Boehringer-Ingel-heim, Ever Neuro Pharma, UCB, Vanquish, Medtronic, and MedLearning; she has participated in advisory boards for UCB Latin America and Teva. T.F. has received honoraria for speaking at meetings sponsored by BIAL, Profile Pharma, Medtronic, Brittania, and AbbVie; he has received grants from the Michael J. Fox Foundation, European Union FP7, the John Black Charitable Foundation, and Brain Research Trust. Z.G. received grants from the Slovak Research and Development Agency and the Slovak Scientific Grant Agency as well as speaker’s honoraria and compensation for consultations from Boehringer-Ingelheim, Pfizer, Bayer, Novartis, and Lundbeck. V.H. received grants from the Slovak Research and Development Agency and the Slovak Scientific Grant Agency as well as speaker’s honoraria and compensation for consultations from Abbvie, Medtronic, and UCB. M.K. has received speaker’s honoraria from UCB and Zambon. J.C.M.C. has received honoraria for speaking at meetings sponsored by AbbVie, UCB, Allergan, Merz, Italfarmaco, BIAL, and KRKA. C.S. received grants from Adamas, Cynapsus, Allergan, Medtronic, the National Parkinson Foundation, and the National Institutes of Health and has received honoraria for panel membership from Neurocrine. P.V. received a grant from the Slovak Scientific Grant Agency as well as speaker’s honoraria and compensation for consultations from Abbvie, Actavis, Krka, Lund-beck, Medtronic, Sanomed, Schwabe Slovakia, TEVA, and UCB. C.G.G. received honoraria for membership, consultancies, or advisory board service from Acadia, Addex, Avanir, Boston Scientific, Clevexel, Oxford Biomedica, Pfizer, WebMD; he is employed by Rush University Medical Center and has a contract with the International Parkinson and Movement Disorder Society for managing translation programs for the MDS-UPDRS and the Unified Dystonia Rating Scale; he has received honoraria from Oregon Health and Science University and the University of Pennsylvania; royalties from Elsevier Publishers, Oxford University Press, Wolters Kluwer; and grants from the National Institutes of Health, the Michael J. Fox Founding, the Parkinson’s Disease Foundation, and International Parkinson and Movement Disorder Society. The remaining authors report no sources of funding and no conflicts of interest.
Publisher Copyright:
© 2017 International Parkinson and Movement Disorder Society
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2017/7/1
Y1 - 2017/7/1
N2 - Background: The Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) is a newly developed tool to assess Parkinson's disease (PD). Changes in scores on the scale over the course of PD, including increasing disease duration and Hoehn and Yahr (HY) stages, have not been described. The objectives of this study were to analyze MDS-UPDRS scores on Parts I through IV and their differences based on HY stage and disease duration in a large cohort of patients with PD. Methods: For this cross-sectional study, demographic data and MDS-UPDRS scores were collected, including HY stage. Subscores on MDS-UPDRS Parts I through IV were analyzed using 1-way analyses of variance for each HY stage and in 5-year increments of disease duration. Part III (motor assessment) scores were analyzed separately for on and off states. Results: The mean age of the 3206 patients was 65.8 ± 10.6 years, 53.3% were men, the mean disease duration was 11.5 ± 4.6 years, and the median HY stage was 2 (range, 0–5); 2156 patients were examined in an on state and 987 were examined in an off state. Scores for all MDS-UPDRS parts increased significantly through HY stages 1 through 5, with an average increase of 3.8, 7.7, 14.6, and 2.0 points consecutively for parts I through IV, respectively. For the 5-year increments of disease duration, MDS-UPDRS subscores increased by an average of 1.6, 3.3, 4.2, and 1.4 points consecutively for parts I through IV, respectively. This increase was significant only during the first 15 years of disease for all 4 parts, including part III scores evaluated in both on and off states. Conclusions: MDS-UPDRS scores for all 4 parts increase significantly with every HY stage and also with 5-year increments of disease duration in the first 15 years of the disease.
AB - Background: The Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) is a newly developed tool to assess Parkinson's disease (PD). Changes in scores on the scale over the course of PD, including increasing disease duration and Hoehn and Yahr (HY) stages, have not been described. The objectives of this study were to analyze MDS-UPDRS scores on Parts I through IV and their differences based on HY stage and disease duration in a large cohort of patients with PD. Methods: For this cross-sectional study, demographic data and MDS-UPDRS scores were collected, including HY stage. Subscores on MDS-UPDRS Parts I through IV were analyzed using 1-way analyses of variance for each HY stage and in 5-year increments of disease duration. Part III (motor assessment) scores were analyzed separately for on and off states. Results: The mean age of the 3206 patients was 65.8 ± 10.6 years, 53.3% were men, the mean disease duration was 11.5 ± 4.6 years, and the median HY stage was 2 (range, 0–5); 2156 patients were examined in an on state and 987 were examined in an off state. Scores for all MDS-UPDRS parts increased significantly through HY stages 1 through 5, with an average increase of 3.8, 7.7, 14.6, and 2.0 points consecutively for parts I through IV, respectively. For the 5-year increments of disease duration, MDS-UPDRS subscores increased by an average of 1.6, 3.3, 4.2, and 1.4 points consecutively for parts I through IV, respectively. This increase was significant only during the first 15 years of disease for all 4 parts, including part III scores evaluated in both on and off states. Conclusions: MDS-UPDRS scores for all 4 parts increase significantly with every HY stage and also with 5-year increments of disease duration in the first 15 years of the disease.
KW - Hoehn and Yahr
KW - Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS)
KW - Parkinson's disease
KW - disease duration
KW - scale
UR - http://www.scopus.com/inward/record.url?scp=85038005840&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85038005840&partnerID=8YFLogxK
U2 - 10.1002/mdc3.12476
DO - 10.1002/mdc3.12476
M3 - Article
AN - SCOPUS:85038005840
VL - 4
SP - 536
EP - 544
JO - Movement Disorders Clinical Practice
JF - Movement Disorders Clinical Practice
SN - 2330-1619
IS - 4
ER -